Compare CCEL & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCEL | NNVC |
|---|---|---|
| Founded | 1989 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Managed Health Care | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.9M | 35.2M |
| IPO Year | 2022 | 2008 |
| Metric | CCEL | NNVC |
|---|---|---|
| Price | $4.56 | $1.33 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 18.2K | ★ 280.1K |
| Earning Date | 04-14-2026 | 05-15-2026 |
| Dividend Yield | ★ 4.26% | N/A |
| EPS Growth | N/A | ★ 10.00 |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $25,384,279.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $59.71 | ★ N/A |
| Revenue Growth | ★ 9.76 | N/A |
| 52 Week Low | $2.72 | $0.85 |
| 52 Week High | $5.01 | $2.23 |
| Indicator | CCEL | NNVC |
|---|---|---|
| Relative Strength Index (RSI) | 70.12 | 40.68 |
| Support Level | $3.10 | $1.26 |
| Resistance Level | $4.41 | $1.47 |
| Average True Range (ATR) | 0.36 | 0.08 |
| MACD | 0.07 | -0.01 |
| Stochastic Oscillator | 68.93 | 17.31 |
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.